These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 36191773)

  • 1. Development of amino acid-modified biodegradable lipid nanoparticles for siRNA delivery.
    Patel P; Fetse J; Lin CY; Guo Y; Hasan MR; Nakhjiri M; Zhao Z; Jain A; Cheng K
    Acta Biomater; 2022 Dec; 154():374-384. PubMed ID: 36191773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.
    Yamamoto Y; Lin PJ; Beraldi E; Zhang F; Kawai Y; Leong J; Katsumi H; Fazli L; Fraser R; Cullis PR; Gleave M
    Clin Cancer Res; 2015 Nov; 21(21):4845-55. PubMed ID: 26106075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient Delivery of Globotriaosylceramide Synthase siRNA using Polyhistidine-Incorporated Lipid Nanoparticles.
    Kim IG; Jung WH; You G; Lee H; Shin YJ; Lim SW; Chung BH; Mok H
    Macromol Biosci; 2023 Apr; 23(4):e2200423. PubMed ID: 36728673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
    Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
    Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Light-Activated siRNA Endosomal Release (LASER) by Porphyrin Lipid Nanoparticles.
    Mo Y; Cheng MHY; D'Elia A; Doran K; Ding L; Chen J; Cullis PR; Zheng G
    ACS Nano; 2023 Mar; 17(5):4688-4703. PubMed ID: 36853331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
    Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
    Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.
    Sato Y; Hashiba K; Sasaki K; Maeki M; Tokeshi M; Harashima H
    J Control Release; 2019 Feb; 295():140-152. PubMed ID: 30610950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid nanoparticles to silence androgen receptor variants for prostate cancer therapy.
    Quick J; Santos ND; Cheng MHY; Chander N; Brimacombe CA; Kulkarni J; van der Meel R; Tam YYC; Witzigmann D; Cullis PR
    J Control Release; 2022 Sep; 349():174-183. PubMed ID: 35780952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo.
    Lee JB; Zhang K; Tam YY; Tam YK; Belliveau NM; Sung VY; Lin PJ; LeBlanc E; Ciufolini MA; Rennie PS; Cullis PR
    Int J Cancer; 2012 Sep; 131(5):E781-90. PubMed ID: 22095615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemistry of Lipid Nanoparticles for RNA Delivery.
    Eygeris Y; Gupta M; Kim J; Sahay G
    Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
    Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
    Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved Stability of siRNA-Loaded Lipid Nanoparticles Prepared with a PEG-Monoacyl Fatty Acid Facilitates Ligand-Mediated siRNA Delivery.
    Sakurai Y; Mizumura W; Ito K; Iwasaki K; Katoh T; Goto Y; Suga H; Harashima H
    Mol Pharm; 2020 Apr; 17(4):1397-1404. PubMed ID: 32091909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
    Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
    Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Charge-reversible lipid derivative: A novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery.
    Hirai Y; Saeki R; Song F; Koide H; Fukata N; Tomita K; Maeda N; Oku N; Asai T
    Int J Pharm; 2020 Jul; 585():119479. PubMed ID: 32473372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancerous pH-responsive polycarboxybetaine-coated lipid nanoparticle for smart delivery of siRNA against subcutaneous tumor model in mice.
    Sung YJ; Guo H; Ghasemizadeh A; Shen X; Chintrakulchai W; Kobayashi M; Toyoda M; Ogi K; Michinishi J; Ohtake T; Matsui M; Honda Y; Nomoto T; Takemoto H; Miura Y; Nishiyama N
    Cancer Sci; 2022 Dec; 113(12):4339-4349. PubMed ID: 36047963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid Nanoparticle (LNP) Chemistry Can Endow Unique
    Johnson LT; Zhang D; Zhou K; Lee SM; Liu S; Dilliard SA; Farbiak L; Chatterjee S; Lin YH; Siegwart DJ
    Mol Pharm; 2022 Nov; 19(11):3973-3986. PubMed ID: 36154076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.
    Xu Y; Ou M; Keough E; Roberts J; Koeplinger K; Lyman M; Fauty S; Carlini E; Stern M; Zhang R; Yeh S; Mahan E; Wang Y; Slaughter D; Gindy M; Raab C; Thompson C; Hochman J
    Mol Pharm; 2014 May; 11(5):1424-34. PubMed ID: 24588618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of siRNA Delivery Targeting the Tumor Microenvironment with a New Functional Device].
    Sakurai Y
    Yakugaku Zasshi; 2019; 139(11):1357-1363. PubMed ID: 31685731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.
    Chen S; Tam YYC; Lin PJC; Sung MMH; Tam YK; Cullis PR
    J Control Release; 2016 Aug; 235():236-244. PubMed ID: 27238441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids.
    Oner E; Kotmakci M; Baird AM; Gray SG; Debelec Butuner B; Bozkurt E; Kantarci AG; Finn SP
    J Nanobiotechnology; 2021 Mar; 19(1):71. PubMed ID: 33685469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.